Atef Ben Nsir1, Yassine Gdoura2, Quoc-Anh Thai3, Alia Zhani Kassar4, Nejib Hattab5, Hafedh Jemel2. 1. Department of Neurosurgery, Fattouma Bourguiba University Hospital-University of Medicine of Monastir, Monastir, Tunisia. Electronic address: atefbn@hotmail.fr. 2. Department of Neurosurgery, The Tunisian National Institute of Neurology-Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia. 3. Department of Neurosurgery, The Johns Hopkins Hospital-The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 4. Department of pathology, La Rabta University Hospital-Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia. 5. Department of Neurosurgery, Fattouma Bourguiba University Hospital-University of Medicine of Monastir, Monastir, Tunisia.
Abstract
BACKGROUND AND IMPORTANCE: Although glioblastoma is the most common primary brain tumor, primary intraventricular locations are extremely rare; only 21 cases have been reported to date. METHODS: A retrospectively acquired database of all intracranial glioblastomas treated in 2 different neurosurgical departments during the last 10 years was queried. Patients with histologically proven intraventricular glioblastomas were included in the study. RESULTS: Eight patients were identified as having a histologically confirmed intraventricular glioblastoma. Patient age at diagnosis ranged from 6 to 74 years (mean 29.6 years) and the male/female ratio was 5:3. Increased intracranial pressure due to hydrocephalus was the main cause of the clinical manifestations. The tumor was located within the lateral ventricle in 6 cases and the anterior third ventricle in 2 others. Gross total tumor excision was achieved in 3 patients, whereas the surgical resection was subtotal in 4 cases and a surgical biopsy was performed in 1 patient. Postoperative adjuvant therapies were administered in 5 patients. Median survival time was 32.1 months, and 3 patients were alive at the end of study. All of them had isocitrate dehydrogenase-mutated tumors. CONCLUSIONS: Intraventricular glioblastoma is extremely rare and can affect younger individuals including children. This malignant tumor should be included in the differential diagnosis of intraventricular lesions, especially in the lateral ventricles. Radical surgical resection can be associated with remarkable disease-free survival, especially in isocitrate dehydrogenase-mutated tumors. Because recurrence virtually is unavoidable, long-term follow-up is mandatory.
BACKGROUND AND IMPORTANCE: Although glioblastoma is the most common primary brain tumor, primary intraventricular locations are extremely rare; only 21 cases have been reported to date. METHODS: A retrospectively acquired database of all intracranial glioblastomas treated in 2 different neurosurgical departments during the last 10 years was queried. Patients with histologically proven intraventricular glioblastomas were included in the study. RESULTS: Eight patients were identified as having a histologically confirmed intraventricular glioblastoma. Patient age at diagnosis ranged from 6 to 74 years (mean 29.6 years) and the male/female ratio was 5:3. Increased intracranial pressure due to hydrocephalus was the main cause of the clinical manifestations. The tumor was located within the lateral ventricle in 6 cases and the anterior third ventricle in 2 others. Gross total tumor excision was achieved in 3 patients, whereas the surgical resection was subtotal in 4 cases and a surgical biopsy was performed in 1 patient. Postoperative adjuvant therapies were administered in 5 patients. Median survival time was 32.1 months, and 3 patients were alive at the end of study. All of them had isocitrate dehydrogenase-mutated tumors. CONCLUSIONS: Intraventricular glioblastoma is extremely rare and can affect younger individuals including children. This malignant tumor should be included in the differential diagnosis of intraventricular lesions, especially in the lateral ventricles. Radical surgical resection can be associated with remarkable disease-free survival, especially in isocitrate dehydrogenase-mutated tumors. Because recurrence virtually is unavoidable, long-term follow-up is mandatory.
Authors: Susan M Irtenkauf; Susan Sobiechowski; Laura A Hasselbach; Kevin K Nelson; Andrea D Transou; Enoch T Carlton; Tom Mikkelsen; Ana C deCarvalho Journal: Comp Med Date: 2017-08-01 Impact factor: 0.982
Authors: Sherif M Elwatidy; Abdulrahman A Albakr; Abdullah A Al Towim; Safdar H Malik Journal: Neurosciences (Riyadh) Date: 2017-10 Impact factor: 0.906